NLRP3 and COVID-19: Thus, inhibition of NLRP3 is also a promising option in treating patients as it has been shown in a mice model that inhibition of the NLRP3 inflammasome attenuated the release of COVID-19-related pro-inflammatory cytokines, and specific inhibition of the NLRP3 inflammasome by MCC950 relieved lung inflammation and pathology in the mice model [149].